Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

Introduction: The phase 3 DUPLEX trial is evaluating sparsentan, a novel, nonimmunosuppressive, single-molecule dual endothelin angiotensin receptor antagonist, in patients with focal segmental glomerulosclerosis (FSGS). Methods: DUPLEX (NCT03493685) is a global, multicenter, randomized, double-blin...

Full description

Saved in:
Bibliographic Details
Main Authors: Howard Trachtman, Jai Radhakrishnan, Michelle N. Rheault, Charles E. Alpers, Jonathan Barratt, Hiddo J.L. Heerspink, Irene L. Noronha, Vlado Perkovic, Brad Rovin, Hernán Trimarchi, Muh Geot Wong, Alex Mercer, Jula Inrig, William Rote, Ed Murphy, Patricia W. Bedard, Sandra Roth, Stewart Bieler, Radko Komers
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Kidney International Reports
Subjects:
dual endothelin angiotensin receptor antagonist
focal segmental glomerulosclerosis
pediatric
race
randomized controlled clinical trial
sparsentan
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024924000421
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2468024924000421

Similar Items